Days
Hours
Minutes
Seconds
-40%
on all subscriptions*
Last days
Enjoy this offer
* See conditions under "Our services"

Valuation: ImmuCell Corporation

Market Cap 87.57M 75.64M 69.7M 65.24M 122M 8.32B 124M 823M 321M 4.05B 329M 322M 14.03B P/E Ratio 2024
-19.5x
P/E Ratio 2025 -51.3x
Enterprise Value 96.96M 83.74M 77.17M 72.24M 135M 9.22B 137M 911M 355M 4.49B 364M 356M 15.53B EV / Sales 2024
2.16x
EV / Sales 2025 2.35x
Free-Float
67.45%
Yield 2024 *
-
Yield 2025 -
1 day-0.62%
1 week+0.73%
Current month-5.47%
1 month+15.51%
3 months+46.00%
6 months+55.88%
Current year+57.40%
1 week 9.52
Extreme 9.52
10.15
1 month 8.26
Extreme 8.26
10.75
Current year 5.75
Extreme 5.75
10.75
1 year 4.52
Extreme 4.52
10.75
3 years 3.34
Extreme 3.34
10.75
5 years 3.34
Extreme 3.34
10.96
10 years 0
Extreme 0
13.2
Manager TitleAgeSince
Chief Executive Officer - 01/11/2025
Director of Finance/CFO 46 07/04/2025
Comptroller/Controller/Auditor - -
Director TitleAgeSince
Chairman 69 21/12/2006
Director/Board Member 61 31/03/2014
Director/Board Member 66 10/06/2020
Date Insider Type Main position Quantity % Market Cap.
15/04Free

Director

11,933 0.1319%
15/04Free

Director

11,933 0.1319%
15/04Free

Director

17,899 0.1979%
Change 5-day change 1-year change 3-year change Capi.($)
-0.62%+0.73%+51.01%+70.12% 87.57M
-2.41%+0.14%+39.53%+154.43% 1,010B
+1.07%+3.48%+53.75%+50.64% 580B
+1.32%+0.22%+18.35%+65.35% 402B
+0.77%0.00%+19.99%+16.80% 330B
-1.42%-1.44%+45.50%+8.37% 294B
-0.85%-2.86%+22.05%+13.80% 280B
+0.44%+3.48%+24.48%+34.39% 281B
+1.66%+1.20%-44.67%-47.49% 197B
+0.32%+1.61%+19.48%+63.42% 192B
Average -0.32%+0.96%+24.95%+42.98% 356.71B
Weighted average by Cap. -0.80%+1.00%+29.84%+66.16%

Financials

2024 2025
Net sales 26.49M 22.88M 21.09M 19.74M 36.99M 2.52B 37.56M 249M 97.07M 1.23B 99.43M 97.31M 4.24B 27.64M 23.88M 22M 20.59M 38.6M 2.63B 39.19M 260M 101M 1.28B 104M 102M 4.43B
Net income -2.16M -1.86M -1.72M -1.61M -3.01M -205M -3.06M -20.27M -7.9M -99.78M -8.09M -7.92M -345M -1.04M -898K -828K -775K -1.45M -98.86M -1.47M -9.77M -3.81M -48.12M -3.9M -3.82M -167M
Net Debt 11.34M 9.8M 9.03M 8.45M 15.83M 1.08B 16.08M 107M 41.56M 525M 42.56M 41.66M 1.82B 9.39M 8.11M 7.47M 6.99M 13.11M 892M 13.31M 88.22M 34.4M 434M 35.23M 34.48M 1.5B
Logo ImmuCell Corporation
ImmuCell Corporation is an animal health company. The Company is engaged in the development, acquisition, manufacture, and sale of products that improve the health and productivity of dairy and beef cattle. It operates in two business segments: Scours and Mastitis. The Scours segment is engaged in manufacturing and selling First Defense, a product used to prevent scours in newborn calves. The Mastitis segment includes products called California Mastitis Test and Re-Tain. Re-Tain, a novel treatment for subclinical mastitis in dairy cows, is in the late stages of development. The First Defense product line provides bovine antibodies that newborn calves need but are unable to produce on their own immediately after birth. Its product line extension, Tri-Shield First Defense, is the first calf-level, passive antibody product providing immediate immunity against each of the three causes of calf scours (E. Coli, coronavirus, and rotavirus).
Employees
73
Date Price Change Volume
12/06/26 9.680 $ -0.62% 9,428
11/06/26 9.740 $ +0.72% 10,938
10/06/26 9.670 $ -1.02% 32,413
09/06/26 9.770 $ +0.72% 17,998
08/06/26 9.700 $ +0.94% 20,814
  1. Stock Market
  2. Stocks
  3. ICCC Stock
- 40% : Our Best Subscriber-Only Tools to Spot Tomorrow’s Top Investments!
d
:
:
SEIZE THE OFFER!